As large AI models absorb functions of traditional SaaS products, investors and entrepreneurs are shifting focus back to tech-enabled services. Integrating AI deeply into physical services and workflows is now seen as creating more defensible, lasting value than pure software, reversing a years-long trend.
In a fast-moving AI landscape, startups can create defensible moats by leveraging new tools to rapidly build solutions for highly specific customer needs. This deep personalization—for a niche provider, rare disease patient, or specific administrative workflow—creates a "wow moment" that large, generalist models struggle to replicate.
The key to treating rare diseases is not just CRISPR technology but a regulatory shift toward an "umbrella" or "platform" strategy. This allows multiple drugs for different mutations to be tested under a single trial, drastically lowering costs and making it feasible to develop treatments for tiny patient populations.
After a year of extensive experimentation, major pharmaceutical companies are now adopting AI at scale, marked by large-scale deals with AI tooling companies. This signals a market inflection point where pharma is moving beyond testing and is actively deploying AI across R&D and commercial functions after seeing demonstrable ROI.